초록 ▼

A computer system comprising a chassis and housing removable servers supported in subchassis, each chassis having optional front or read cable access. Power and signal connectivity to the servers may be made from the front or rear of the system. The subchassis may be half the width of the chassis or

A computer system comprising a chassis and housing removable servers supported in subchassis, each chassis having optional front or read cable access. Power and signal connectivity to the servers may be made from the front or rear of the system. The subchassis may be half the width of the chassis or a quarter of a width of the chassis. The subchassis further include an upper bay and a lower bay as well as a plurality of field replaceable units, which all may be access through the front of the chassis. One or more of the field replaceable units connect to the system through a midplane, located within the subchassis.

대표청구항 ▼

A computer system comprising a chassis and housing removable servers supported in subchassis, each chassis having optional front or read cable access. Power and signal connectivity to the servers may be made from the front or rear of the system. The subchassis may be half the width of the chassis or

A computer system comprising a chassis and housing removable servers supported in subchassis, each chassis having optional front or read cable access. Power and signal connectivity to the servers may be made from the front or rear of the system. The subchassis may be half the width of the chassis or a quarter of a width of the chassis. The subchassis further include an upper bay and a lower bay as well as a plurality of field replaceable units, which all may be access through the front of the chassis. One or more of the field replaceable units connect to the system through a midplane, located within the subchassis. on is administered vaginally. 16. The method of claim 15, wherein the pharmaceutical formulation is in the form of an ointment, cream, gel, solid, solution, suspension, foam or liposomal composition. 17. The method of claim 15, wherein the pharmaceutical formulation is contained within a vaginal ring, tampon, suppostory, sponge, pillow, puff, or osmotic pump system. 18. The method of claim 14, wherein the formulation is administered to the vulvar area. 19. A method for improving vaginal muscle tone and tissue health in a female individual, comprising vaginally administering to such individual therapeutically effective amounts of (a) a prostaglandin selected from the group consisting of naturally occurring prostaglandins, semisynthetic prostaglandin derivatives, synthetic prostaglandin derivatives, pharmacologically acceptable salts, esters, and inclusion complexes thereof, and combinations of any of the foregoing, and (b) an androgenic agent. 20. A method for enhancing vaginal lubrication in a female individual, comprising vaginally administering to such individual therapeutically effective amounts of (a) a prostaglandin selected from the group consisting of naturally occurring prostaglandins, semisynthetic prostaglandin derivatives, synthetic prostaglandin derivatives, pharmacologically acceptable salts, esters, and inclusion complexes thereof and combinations of any of the foregoing, and (b) an androgenic agent. 21. The method of claim 1, wherein the androgenic agent is selected from the group consisting of androsterone, androsterone acetate, androsterone, androstenediol, androstenedione, ethylestrenol, oxandrolone, nandrolone, stanozolol, dromostanolone, testosterone, dehydroepiandrosterone, 5α-dihydrotestosterone, methyl testosterone, testolactone, oxymetholone, fluoxymesterone, and pharmaceutically acceptable esters thereof. 22. The method of claim 21, wherein the androgenic agent is selected from the group consisting of testosterone, 5α-dihydrotestosterone, and pharmaceutically acceptable esters thereof. 23. The method of claim 22, wherein the androgenic agent is testosterone. 24. The method of claim 22, wherein the androgenic agent is 5α-dihydrotestosterone. 25. The method of claim 22, wherein the androgenic agent is a testosterone ester. 26. The method of claim 25, wherein the testosterone ester is selected from the group consisting of testosterone enanthate, testosterone propionate, testosterone cypionate, testosterone phenylacetate, testosterone acetate, testosterone isobutyrate, testosterone buciclate, testosterone heptanoate, testosterone decanoate, testosterone undecanoate, testosterone caprate and testosterone isocaprate. 27. The method of